Technology

Evaxion Biotech is pioneering discovery of prophylactic vaccines and therapeutic antibodies using Artificial Intelligence.

Our two platforms PIONEER and EDEN are utilizing the power of artificial intelligence, big data and supercomputing, to discover efficacious vaccines fast at almost no cost. The technologies have been programmed to identify the most suitable targets for vaccines and antibodies by integrating big data, artificial intelligence and supercomputing in one platform, thereby enabling rapid and accurate discovery of novel antigens and epitopes.

Technology

Evaxion Biotech is pioneering discovery of prophylactic vaccines and therapeutic antibodies using Artificial Intelligence.

Our two platforms PIONEER and EDEN are utilizing the power of artificial intelligence, big data and supercomputing, to discover efficacious vaccines fast at almost no cost. The technologies have been programmed to identify the most suitable targets for vaccines and antibodies by integrating big data, artificial intelligence and supercomputing in one platform, thereby enabling rapid and accurate discovery of novel antigens and epitopes.

PIONEER

PIONEER is Evaxion’s immuno-oncology platform from which truly personalized cancer immunotherapies can be developed. The platform uses sophisticated algorithms to identify and select the neoepitopes, tumor-specific mutations, that are most likely to generate a profound anti-cancer immune response. The identified neoepitopes are used in a therapeutic immunization strategy which delivers personalized synthetic neoepitopes to patients by vaccination.

Evaxion has improved the prediction power of PIONEER to supersede state of the art and stands out by incorporating vaccine modality specific predictions, thus ensuring the right neo-epitopes for the right vaccine technology.

EDEN

The key strength of EDEN is the ability to identify novel protein antigens that elicit highly protective immune responses against a broad range of pathogen sub-strains. This groundbreaking fast technology enables the discovery of highly and broadly protective vaccine candidates in a matter of hours.

Taking advantage of the rapid increase in big data from modern high throughput sequencing studies, EDEN takes proteomes from clinically relevant pathogen strains as input. Using specialized machine learning methods, EDEN targets immune evasion strategies of bacteria and outputs a list of proteins ranked by their ability to elicit a broad and highly protective immune response.

EDEN can be applied in the discovery of novel antigens against serious infectious diseases and can help bring novel vaccines and antibodies to patients at unprecedented pace.

© Copyright 2018 EVAXION BIOTECH All rights reserved